

10/586382

Attorney's Docket No. 007157/314050

JAP20 Rec'd PCT/PTO 19 JUL 2006

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Kalman *et al.*

Attn: DO/US

International Appl. No.: PCT/US2005/001710

International Filing Date: January 20, 2005

For: COMPOSITIONS AND USE OF TYROSINE KINASE INHIBITORS TO TREAT
PATHOGENIC INFECTION

Mail Stop PCT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

The patents listed on the attached PTO-1449 were cited in the International Search Report of corresponding International Application No. PCT/US2005/001710. A copy of the Search Report is enclosed for the Examiner's convenience. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

The Examiner may wish to consider the notations on the Search Report itself regarding the relevance of each item. It is requested that the Examiner consider these references and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.


Respectfully submitted,



Edward R. Ergenzinger
Registration No. 47,549

ALSTON & BIRD LLP
Bank of America Plaza
101 South Tryon Street, Suite 4000
Charlotte, NC 28280-4000
Tel Raleigh Office (919) 862-2200
Fax Raleigh Office (919) 862-2260
Customer No. 00826

"Express Mail" Mailing Label Number EV 913517380 US
Date of Deposit: July 19, 2006
I hereby certify that this paper or fee is being deposited with the United States
Postal Service "Express Mail Post Office to Addressee" service under 37 CFR
1.10 on the date indicated above and is addressed to Mail Stop PCT,
Commissioner for Patents, Alexandria, VA 22313-1450.


Karyn Grimm

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

107586382

Substitute for form 1449/PTO (Revised 07/2005)		Complete if Known	
		Application Number	Not yet assigned
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	Herewith
<i>(Use as many sheets as necessary)</i>		First Named Inventor	Kalman
Sheet	2	of	2
		Group Art Unit	Not yet assigned
		Examiner Name	Not yet assigned
		Attorney Docket Number	007157/314050

OTHER DOCUMENTS

Examiner Initials*	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume/issue number(s), publisher, city and/or country where published.	English Language Translation Attached
	7	DORSEY, J., <i>et al.</i> , "Interleukin-3 Protects Bcr-Abl-transformed Hematopoietic Progenitor Cells from Apoptosis Induced by Bcr-Abl Tyrosine Kinase Inhibitors," <i>Leukemia</i> , 2002, pp. 1589-1595, Vol. 16, Nature Publishing Group.	
	8	DUMÉNIL, G., <i>et al.</i> , "Interferon α Inhibits a Src-mediated Pathway Necessary for <i>Shigella</i> -induced Cytoskeletal Rearrangements in Epithelial Cells," <i>The Journal of Cell Biology</i> , 1998, pp. 1003-1012, Vol. 143(4), The Rockefeller University Press.	
	9	HUANG, M., <i>et al.</i> , "Inhibition of Bcr-Abl Kinase Activity by PD180970 Blocks Constitutive Activation of Stat5 Growth of CML Cells," <i>Oncogene</i> , 2002, pp. 8804-8816, Vol. 21, Nature Publishing Group.	
	10	KRAKER, A., <i>et al.</i> , "Biochemical and Cellular Effects of c-Src Kinase-Selective Pyrido[2,3- <i>d</i>]pyrimidine Tyrosine Kinase Inhibitors," <i>Biochemical Pharmacology</i> , 2000, pp. 885-898, Vol. 60, Elsevier Science Inc.	
	11	QIE, L., <i>et al.</i> , "Herpes Simplex Virus Entry is Associated with Tyrosine Phosphorylation of Cellular Proteins," <i>Virology</i> , 1999, pp. 220-227, Vol. 256, Academic Press.	
	12	SELBACH, M., <i>et al.</i> , "Src is the Kinase of the <i>Helicobacter Pylori</i> CagA Protein <i>in Vitro</i> and <i>in Vivo</i> ," <i>The Journal of Biological Chemistry</i> , 2002, pp. 6775-6778, Vol. 277(9), The American Society for Biochemistry and Molecular Biology, Inc.	
	13	TANG, P., <i>et al.</i> , " <i>Listeria Monocytogenes</i> , an Invasive Bacterium, Stimulates MAP Kinase upon Attachment to Epithelial Cells," <i>Molecular Biology of the Cell</i> , 1994, pp. 455-464, Vol. 5, The American Society for Cell Biology.	
	14	VANICHKIN, A., <i>et al.</i> , "Late Administration of a Lipophilic Tyrosine Kinase Inhibitor Prevents Lipopolysaccharide and <i>Escherichia Coli</i> -induced Lethal Toxicity," <i>The Journal of Infectious Diseases</i> , 1996, pp. 927-933, Vol. 173, The University of Chicago.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.